Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 1/2 25Phase 1 14Phase 3 11Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 8Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3Gemcitabine 3Bendamustine Hydrochloride 3prednylidene 2deltacortene 2Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2CT-P10 2Busulfan 2venetoclax 1umbralisib 1ublituximab 1tebufenozide 1tafasitamab 1selinexor 1huachansu 1fludarabine phosphate 1epratuzumab 1cc-486 1Whole-Body Irradiation 1Vindesine 1VAP-cyclo protocol 1Thiotepa 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Large B-Cell, Diffuse × Lenalidomide × Clear all
NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡